Examkin

Question

Difficulty: MediumRheumatology and Immunology

A 24-year-old woman presents to the outpatient clinic with a 3-month history of severe fatigue, symmetric pain in her bilateral wrists and metacarpophalangeal joints, and a photosensitive erythematous rash over her cheeks and nasal bridge. She is suspected of having a new-onset systemic autoimmune connective tissue disease. Arrange the following diagnostic and therapeutic steps in the appropriate clinical and chronological sequence for her suspected condition, starting from initial screening to the management of potential severe complications.

  1. 1Perform initial serologic screening with an antinuclear antibody (ANA) test.
  2. 2Obtain highly specific confirmatory serologies, such as anti-dsDNA and anti-Smith antibodies, following a positive screening test.
  3. 3Initiate foundational disease-modifying therapy with hydroxychloroquine to reduce flares and improve survival.
  4. 4Escalate therapy to include potent immunosuppressants, such as mycophenolate mofetil, if severe manifestations like lupus nephritis develop.

Answer

The correct clinical sequence for Systemic Lupus Erythematosus (SLE) is: 1) Initial screening with an ANA test, 2) Diagnostic confirmation with anti-dsDNA and anti-Smith antibodies, 3) Baseline maintenance therapy with hydroxychloroquine, and 4) Escalation to potent immunosuppressants (e.g., mycophenolate mofetil) only if severe organ involvement occurs.
The standard approach to a patient with suspected systemic lupus erythematosus (SLE) begins with highly sensitive serologic screening (ANA test). If the screening is positive, highly specific markers (anti-dsDNA, anti-Smith) are checked to confirm the diagnosis. Once confirmed, hydroxychloroquine is the cornerstone of SLE management and is indicated for all patients to control constitutional symptoms, musculoskeletal manifestations, and cutaneous findings, as well as to prevent future flares. Step-up therapy to potent immunosuppressants (such as mycophenolate mofetil or cyclophosphamide) is strictly reserved for severe, life-threatening, or organ-threatening complications, such as lupus nephritis or central nervous system involvement.

Step-by-Step Solution

1
Identify the suspected diagnosis based on the clinical vignette.
The patient has a classic presentation of Systemic Lupus Erythematosus (SLE), characterized by fatigue, polyarthritis, and a malar rash.
Recognizing the clinical pattern is required to determine the appropriate diagnostic pathway.
2
Determine the initial diagnostic screening test.
The antinuclear antibody (ANA) test should be ordered first.
ANA is highly sensitive (greater than 95% in SLE) and is the most appropriate initial screening test to rule out the disease if negative.
3
Identify the confirmatory diagnostic step.
Anti-dsDNA and anti-Smith antibodies are ordered next.
These autoantibodies are highly specific for SLE and are used to confirm the diagnosis in patients with a positive ANA and consistent clinical features.
4
Determine the initial pharmacologic management.
Hydroxychloroquine should be initiated.
Current guidelines recommend hydroxychloroquine for all patients with SLE, regardless of severity, to prevent flares, reduce organ damage, and improve long-term survival.
5
Identify the appropriate indication for treatment escalation.
Mycophenolate mofetil or cyclophosphamide is added for severe disease.
These agents are highly potent immunosuppressants with significant toxicity profiles; therefore, they are strictly reserved for subsequent severe organ-threatening complications like lupus nephritis.

Key Concept

Diagnostic and therapeutic sequencing in Systemic Lupus Erythematosus (SLE)
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic